Click here to subscribe to our Free Newsletter

Previous News

Pan-Canadian Oncology Drug Review (pCODR)

A pan-Canadian Oncology Drug Review (pCODR) information session for pharmaceutical manufacturers has been is scheduled for September 22, 2011, and pharmaceutical manufacturers are required to RSVP by September 19, 2011. Please see the pCODR Update for more information.

The pan-Canadian Oncology Drug Review (pCODR) has released a statement, dated July 7, 2011, announcing that it will start accepting submissions on July 13, 2011. From July 13, 2011 to August 12, 2011, manufacturers will have the choice to submit their drug for review either under the interim Joint Oncology Drug Review (iJODR) process or the pCODR process. All pCODR-eligible products must go through the pCODR process as of August 15, 2011.

For more information, and for a copy of the pCODR Pre-Submission Guidelines, please visit the pCODR website.

The pan-Canadian Oncology Drug Review (pCODR) has released an announcement dated March 14, 2011. Dr. Anthony Fields, MD, FRCPC, FACP has been appointed as Chair of the pCODR Expert Review Committee (pERC). Dr. Fields is currently Vice President of the Alberta Health Services – Cancer Care and is a professor in the Department of Oncology at the University of Alberta. Dr. Fields was also a member of the Steering Committee of the interim Joint Oncology Drug Review (iJODR) and a member of the Steering Committee of the pCODR program.

The role of the pCODR Expert Review Committee is to assess the clinical evidence and cost effectiveness of cancer drugs, and to use this information to make recommendations to the provinces and territories to guide their drug funding decisions.

pCODR has released pCODR Communication update 5B, dated February 4, 2011. Highlights include:

pCODR anticipates accepting new submissions in April 2011, rather than the end of February as initially planned.
pCODR is encouraging drug manufacturers who are planning to submit a drug for review in the first quarter of the 2011/2012 fiscal year (or later) to email info@pcodr.ca to initiate pre-submission discussions.
Drug manufacturers who are planning to submit a drug for review before March 31, 2011 are encouraged to contact the iJODR team directly and immediately.